Gilead Sciences - GS-6637's Unit Acquisition

Gilead Sciences - GS-6637 raised a round of funding on February 16, 2017. Investors include Amygdala Neurosciences.

Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for viral diseases, infectious diseases and cancerutilized proprietary "combinatorial…

Articles about Gilead Sciences - GS-6637's Unit Acquisition: